Funder
Natural Science Foundation of Inner Mongolia Autonomous Region
Natural Science Foundation of Tianjin Municipal Science and Technology Commission
Nanjing Municipal Health Bureau
National Natural Science Foundation of China
Reference40 articles.
1. The pathogenesis of sepsis and potential therapeutic targets;Huang;Int. J. Mol. Sci.,2019
2. Clinical trials in acute respiratory distress syndrome: challenges and opportunities, Lancet;Matthay;Respir. Med.,2017
3. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery;Park;ACS Pharmacol Transl Sci,2020
4. Zhao MM, Zheng ZH, Yin Z, Zhang JS, Qin JJ, Wan J, Wang ML, Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target, Pharmacol Res 195(2023) http://ARTN 106832. 10.1016/j.phrs.2023.106832.
5. Protective actions of aspirin-triggered (17R) resolvin D1 and its analogue, 17R-hydroxy-19-para-fluorophenoxy-resolvin D1 methyl ester, in C5a-dependent IgG immune complex-induced inflammation and lung injury;Tang;J. Immunol.,2014